BioNTech Eyes First Oncology Approvals By 2026
Company Inks Antibody Discovery Deal With WuXi
The biotech's CEO told the J.P. Morgan Healthcare Conference that the company aims to have multiple oncology products on the market by 2029, but it plans to retain a large presence in vaccines as well.
